Ankyra Medical Journal (AnkMJ), formerly known as the Journal of Translational and Practical Medicine, regularly publishes international quality issues in the field of Medicine in the light of current information.

EndNote Style
Original Article
Efficacy of ferric carboxymaltose therapy in celiac patients
Aims: Iron deficiency anemia (IDA) is the most common cause of anemia worldwide. IDA can be caused by reduced iron intake, impaired iron absorption or losses. Celiac disease can cause iron malabsorption by decreasing the surface absorption area in the duodenum and consequently can cause IDA. Oral or intravenous iron preparations are used in the treatment of IDA. In this study, we wanted to investigate the efficacy of ferric carboxymaltose (FCM) in celiac patients with RIA.
Methods: Twenty-three patients who were followed up in the gastroenterology outpatient clinic of İnönü University Medical Faculty Hospital Turgut Özal Medical Center with the diagnosis of CD and who received FCM were included in the study. The hemogram, ferritin, iron and iron binding levels of the patients were retrospectively screened through the hospital medical record system.
Results: Of the 23 patients included in the study, 3 (13.05%) were male and 20 (86.95%) were female. Hemoglobin concentration, iron and iron binding capacity before and after treatment showed a significant increase in all parameters after treatment. Ferritin value increased, although not significantly.
Conclusion: In our study, we found that FCM is an effective and safe treatment modality in the treatment of IDA in celiac patients.

1. Elstrott B, Khan L, Olson S, Raghunathan V, DeLoughery T, Shatzel JJ. The role of iron repletion in adult iron deficiency anemia and other diseases. Eur J Haematol. 2020;104(3):153-161.
2. Kumari R, Bharti RK, Singh K, et al. Prevalence of iron deficiency and iron deficiency anaemia in adolescent girls in a tertiary care hospital. J Clin Diagn Res. 2017;11(8):BC04-BC06.
3. Bregman DB, Goodnough LT. Experience with intravenous ferric carboxymaltose in patients with iron deficiency anemia. Ther Adv Hematol. 2014;5(2):48-60.
4. World Health Organization. Iron deficiency anemia. assessment, prevention, and control. A guide for programme managers. 2001;47-62.
5. Koduru P, Abraham BP. The role of ferric carboxymaltose in the treatment of iron deficiency anemia in patients with gastrointestinal disease. Therap Adv Gastroenterol. 2016;9(1):76-85.
6. Lyseng-Williamson KA, Keating GM. Ferric carboxymaltose: a review of its use in iron-deficiency anaemia. Drugs. 2009;69(6):739-56.
7. Ballester-Clau R, Torres Vicente G, Cucala Ramos M, et al. Efficacy and safety of treatment with ferric carboxymaltose in patients with cirrhosis and gastrointestinal bleeding. Front Med (Lausanne). 2020;17(7):128.
8. Bailie GR. Efficacy and safety of ferric carboxymaltose in correcting iron-deficiency anemia: a review of randomized controlled trials across different indications. Arzneimittelforschung. 2010;60(6a):386-98.
9. Stefanelli G, Viscido A, Longo S, Magistroni M, Latella G. Persistent iron deficiency anemia in patients with celiac disease despite a gluten-free diet. Nutrients. 2020;12(8):2176.
10. Shahriari M, Honar N, Yousefi A, Javaherizadeh H. Association of potential celiac disease and refractory iron deficiency anemia in children and adolescents. Arq Gastroenterol. 2018;55(1):78-81.
11. Talarico V, Giancotti L, Mazza GA, Miniero R, Bertini M. Iron deficiency anemia in celiac disease. Nutrients. 2021;13(5):1695.
12. Hussain I, Bhoyroo J, Butcher A, Koch TA, He A, Bregman DB. Direct Comparison of the Safety and Efficacy of Ferric Carboxymaltose versus Iron Dextran in Patients with Iron Deficiency Anemia. Anemia. 2013; 69107.
Volume 3, Issue 3, 2024
Page : 66-68